Home > Formulary : Paediatric > Paediatric Chapters > 13. Skin >
BNSSG Paediatric Joint Formulary
13.3 Inflammatory skin conditions
Last edited: 16-07-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
13.3.1 Eczema and Psoriasis
Antracen Derivatives
Recommended:
Dithranol in Lassar’s paste 0.1 to 2% (TLS Red)
- Only on prescription by a Clinician experienced in skin disease (TLS Red)
- Dithranol in Lassar’s Paste are only available as ‘special’ preparations (i.e. not proprietary products). These preparations are not cost-effective in primary care and there may be a significant delay in obtaining such preparations
- Arachis oil (TLS Green) should be prescribed to remove the Dithranol in Lassar’s Paste. Arachis oil contains peanuts
Bacteriostatics
Zinc paste bandages (Ichthopaste®, Viscopaste®, Zipzoc®) (TLS Green)
Calcineurin Inhibitors and Related Drugs
Pimecrolimus 1% cream (Elidel®) (TLS Amber)
- Only on prescription by a Clinician experienced in skin disease
- Short term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used
- Outside of SPC indication, this is TLS RED
Tacrolimus 0.03% ointment (Protopic®) (TLS Green)
- Only on prescription by a Clinician experienced in skin disease
- For use in moderate to severe atopic dermatitis unresponsive to conventional therapies. Within SPC use only, in accordance with NICE TA82
Tacrolimus 0.1% ointment (Protopic®) (TLS Amber Specialist Recommended)
Corticosteroids
Mild
Hydrocortisone 0.5, 1% cream/ointment (TLS Green)
Hydrocortisone 1% / Miconazole nitrate 2% cream / ointment (Daktacort®) (TLS Green)
Hydrocortisone 1% / Clotrimazole 1% cream (Canesten HC) (TLS Green)
Moderate
Clobetasone butyrate 0.05% cream / ointment (Eumovate®) (TLS Green)
Betamethasone 0.025% cream / ointment (Betnovate RD®) (TLS Green)
Clobetasone butyrate 0.05% / Oxytetracycline 3% / Nystatin 100,000 units/g cream (Trimovate®) (TLS Green)
Fluocinolone 0.00625% (Synalar® 1 in 4) ointment and cream (TLS Blue)
- As per licensed indications
Potent
Betamethasone 0.1% cream / ointment/lotion (Betnovate®) (TLS Green)
Betamethasone 0.05% / Salicylic acid 3% ointment (Diprosalic®) (TLS Green)
Mometasone furoate 0.1% cream / ointment (Elocon®) (TLS Green)
Fludroxycortide tape (Haelan®) (TLS Green)
Synalar (Fluocinolone 0.025%) gel / ointment / cream (TLS Blue)
Very Potent
Clobetasol propionate 0.05% cream / ointment (Dermovate®) (TLS Amber Specialist Recommended)
Clobetasol propionate 0.05% / Neomycin sulphate 0.5% / Nystatin 100,000 units/g cream / ointment (TLS Amber Specialist Recommended)
Other Preparations
Hydroquinone 5% / Hydrocortisone 1% / Tretinoin 0.1% cream (Pigmanorm®) (TLS Red)
Specific indication:
Dermovate® with 40% Propylene glycol (TLS Red)
- Specialist Consultant use only for the treatment of Severe hyperkeratotic psoriasis and eczema of the palms and/or soles for 4 weeks (Unlicensed)
Retinoid and Related Drugs
Recommended:
Acitretin (TLS Red)
Alitretinoin (TLS Red)
Tars
Recommended:
Exorex® lotion (TLS Green)
Sebco® scalp ointment (TLS Green)
Coal tar / Salicylic acid ointment (TLS Green)
- Coal Tar and Salicylic Acid ointments are only available as ‘special’ preparations (i.e. not proprietary products). These preparations are not cost-effective in primary care and there may be a significant delay in obtaining such preparations.
Vitamin D and Analogues
Recommended:
Calcipotriol / Betamethasone 0.05% (Dovobet®) (TLS Green)
Calcipotriol ointment (TLS Green)
Drugs Affecting the Immune Response
Azathioprine (oral) (TLS Red)
Ciclosporin (oral) (TLS Red)
Methotrexate - weekly dose (TLS Amber 1 month) (SCP click here)
Mycophenolate (oral) (TLS Red)
- N.B. unlicensed for eczema and skin conditions
- Used only by specialists
Cytokine Modulators
- As per NICE’s biosimilar position statement, if the originator biologic product is on the BNSSG joint formulary, the new biosimilar product will also be included on the formulary in accordance with its UK licence when it becomes commercially available
Recommended: (TLS Red)
Abrocitinib (oral)
- NICE TA814 Abrocitinib or upadacitinib for treating moderate to severe atopic dermatitis in young people 12 years and over
Adalimumab (parenteral)
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- As per NICE TA146
- NICE TA392 For severe hidradenitis suppurativa. Commissioned by NHS England
Dupilumab (parenteral)
- NICE TA534 Dupilumab for treating moderate to severe atopic dermatitis
Etanercept (parenteral)
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- As per NICE TA103
Infliximab (parenteral)
Secukinumab (parenteral)
- As per NICE TA350
- NICE TA734 Secukinumab for treating severe plaque psoriasis in children and young people
Ustekinumab (parenteral)
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- As per NICE TA180
- Please refer to NPSA guidance on reducing the risks of oral methotrexate. Patients should have patient held records while they are receiving treatment with any DMARD requiring regular monitoring (record cards and GP protocol advice available from rheumatology)
- Tacrolimus ointment is classified TLS green when used within the SPC and red when used outside of the SPC
- Please refer to Chapter 8 for systemic preparations
Upadacitinib (oral)
- NICE TA814 Abrocitinib or upadacitinib for treating moderate to severe atopic dermatitis in young people 12 years and over